Background Half of new HIV acquisitions in Africa occur in adolescent girls and young
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …

Background HIV incidence among adolescents in southern Africa remains unacceptably
high. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention intervention but there …

Background: Adolescent girls and young women (AGYW) account for most new HIV
infections in sub-Saharan Africa. WHO has endorsed oral PrEP and dapivirine vaginal ring …

Introduction Oral tenofovir disoproxil fumarate/emtricitabine pre‐exposure prophylaxis
(PrEP), introduced into South Africa (SA) in 2016, has increasingly become part of HIV …

Introduction Adolescent girls and young women (AGYW) in sub-Saharan Africa are
disproportionately affected by the HIV epidemic and face an array of challenges using …

Introduction Adolescent girls and young women (AGYW) in Africa have high HIV incidence
despite scale‐up of HIV testing and HIV treatment. Placebo‐controlled trials of tenofovir …

Background Adolescent girls and young women in southern and eastern Africa have
adherence challenges with daily oral HIV pre-exposure prophylaxis (PrEP). High adherence …

Introduction The burden of HIV in sub‐Saharan Africa (SSA) remains unacceptably high,
and disproportionately affects girls and women. While the introduction of oral HIV pre …

Background In sub-Saharan Africa (SSA), adolescent girls and young women (AGYW) ages
15 to 24 years represent< 10% of the population yet account for 1 in 5 new HIV infections …

Introduction HIV incidence remains high among African adolescent girls and young women
(AGYW), who would benefit from pre‐exposure prophylaxis (PrEP). Strategies to increase …